Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Subject category: Entrepreneurship
Published by: International Institute for Management Development (IMD)
Originally published in: 2022
Version: 26.01.2022
Revision date: 11-Feb-2022

Abstract

This is part of a case series. The A case tells the story of Anthony Giovinazzo's entrepreneurial journey with Cyna Pharma, which he built from the ground up. Cyna Pharma was a Canada-based specialty pharmaceutical company that was at the point of conducting Phase 3 clinical trials in 2016 for its main product: APL-130277 - a novel delivery mechanism for an existing drug called apomorphine, used for on-demand treatment of the debilitating off-episodes (freezing) associated with Parkinson's disease (PD). The case provides an overview of Anthony's unique background, the off-episodes associated with Parkinson's disease, the specialty biopharma sector, the funding rounds to get to Phase 3 clinical trials and the brushes with disaster along the way. It also describes the steps to getting listed on the NASDAQ and the benefits of doing so. After an earlier offer to acquire the company the case ends with a similar offer from Sundown Pharma a year later. As the case comes to a close, Anthony is faced with a moment of truth: Should he move forward with launching the product himself, or should he license his product with a partner or agree to an outright acquisition by a big pharma company?

Time period

The events covered by this case took place in 2002-2016.

Geographical setting

Country:
Canada

Featured company

Cyna Pharma (Disguised)
Turnover:
USD 624 million
Industry:
Biopharmaceuticals

About

Abstract

This is part of a case series. The A case tells the story of Anthony Giovinazzo's entrepreneurial journey with Cyna Pharma, which he built from the ground up. Cyna Pharma was a Canada-based specialty pharmaceutical company that was at the point of conducting Phase 3 clinical trials in 2016 for its main product: APL-130277 - a novel delivery mechanism for an existing drug called apomorphine, used for on-demand treatment of the debilitating off-episodes (freezing) associated with Parkinson's disease (PD). The case provides an overview of Anthony's unique background, the off-episodes associated with Parkinson's disease, the specialty biopharma sector, the funding rounds to get to Phase 3 clinical trials and the brushes with disaster along the way. It also describes the steps to getting listed on the NASDAQ and the benefits of doing so. After an earlier offer to acquire the company the case ends with a similar offer from Sundown Pharma a year later. As the case comes to a close, Anthony is faced with a moment of truth: Should he move forward with launching the product himself, or should he license his product with a partner or agree to an outright acquisition by a big pharma company?

Settings

Time period

The events covered by this case took place in 2002-2016.

Geographical setting

Country:
Canada

Featured company

Cyna Pharma (Disguised)
Turnover:
USD 624 million
Industry:
Biopharmaceuticals

Related